Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth

Yuebo Zhang, Yong Ma, Ying Wang, Debabrata Mukhopadhyay, Yan Bi, Baoan Ji

Research output: Contribution to journalArticlepeer-review


Pancreatic ductal adenocarcinoma (PDAC) is notorious for high mortality due to limited options of appropriate chemotherapy drugs. Here we report that Aurora kinase-A expression is elevated in both human and mouse PDAC samples. MLN8237, an inhibitor of Aurora kinase-A, efficiently reduced the proliferation and motility of PDAC cells in vitro as well as tumor growth in orthotropic xenograft model and genetic pancreatic cancer animal models (p53/LSL/Pdx-Cre mice) in vivo. MLN8237 exhibited tumor inhibitory effect through inhibiting proliferation and migration, and inducing apoptosis and senescence. These results provide the molecular basis for a novel chemotherapy strategy for PDAC patients.

Original languageEnglish (US)
Pages (from-to)619-625
Number of pages7
Issue number5
StatePublished - Jun 2022


  • Apoptosis
  • Aurora kinase
  • Pancreatic cancer
  • Senescence
  • Xenograft

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth'. Together they form a unique fingerprint.

Cite this